Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)

The summary for the Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed): The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.

Federal Grant Title:	Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-24-151
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.242
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 17th, 2023
Original Application Deadline:	October 17th, 2023
Posted Date:	July 12th, 2023
Creation Date:	July 12th, 2023
Archive Date:	November 22nd, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 12th, 2023

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see NOFO for eligibility details
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-151.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health D...; • Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Re...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed); • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...; • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...; • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...; • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...